Libtayo, or cemiplimab-rwlc, a PD-1 inhibitor developed by Regeneron Pharmaceuticals and Sanofi, was approved by the FDA as a first-line treatment for certain patients with advanced non-small cell lung cancer. Conditions for use include having a high PD-L1 expression, metastatic tumors not eligible for surgical resection or definitive chemoradiation, and tumors without EGFR, ALK or ROS1 aberrations.
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.